Bristol Myers Squibb announced a strategic collaboration with the Sarah Cannon Research Institute (SCRI), an oncology research organization conducting community-based clinical trials, on November 12th, 2025. According to a company press release, the collaboration aims to launch various clinical trials from Bristol Myers’ oncology pipeline at SCRI’s network of more than 200 locations across over 20 states, further scaling an ongoing collaboration between the two companies.

According to the release, the early phase of the collaboration saw SCRI reduce study startup timelines by 45% across eight Bristol Myers clinical trials relative to non-SCRI sites. By increasing the scale of their collaboration, the partnership aims to enable broader participation in clinical trials while simultaneously speeding the overall development of various oncology treatments.

“At Bristol Myers Squibb, we recognize that accelerating clinical trial enrollment requires not only scientific innovation but also operational innovation. This includes a deep commitment to equity and inclusion, while we look to accelerate overall patient enrollment,” said Mokash Sharma, Senior Vice President, Global Development Operations, Bristol Myers Squibb, in the release. “Improving access to clinical research isn’t just about science—it’s about trust, and meeting people where they are. By leveraging data-driven strategies through our collaboration with Sarah Cannon Research Institute, we’re working to ensure that more patients—especially those from medically underserved populations—have access to vital cancer research advances in their communities. This partnership reflects our shared vision to transform clinical trial delivery and advance health equity across the oncology landscape.”

“Together, SCRI and Bristol Myers Squibb are translating innovative science into clinical trials and accelerating patient enrollment through SCRI’s Accelero model that prioritizes speed, quality, and access, and ultimately brings promising therapies to patients faster and closer to home,” said Dee Anna Smith, CEO, SCRI, in the release. “We look forward to the impact we will have together as we reach more patients and continue to redefine how clinical trials are delivered across the country.”